Icon

ATARAX (nda010392)- (10MG,25MG,50MG,100MG)

HYDROXYZINE HYDROCHLORIDE PFIZER
10MG,25MG,50MG,100MG
No No
Expired Expired
None None
None No
ATARAX is indicated for symptomatic relief of anxiety and tension associated with psychoneurosis and as an adjunct in organic disease states in which anxiety is manifested. Useful in the management of pruritus due to allergic conditions such as chronic urticaria and atopic and contact dermatoses, and in histamine-mediated pruritus.
17 0 12
Total Other Developers 1
Drugs with Suitability No
10MG ** ** - - 6
25MG ** ** - 6 1
50MG ** ** - 5 1
100MG ** ** - - -
NDA Sales Available Total Generic Sales Available
No 7
ANDA No Generic Co Manufacturer Name Operations Manufacturer Address Country
****** *** **** ***-****, ***. *********** *** ***** **., *******, ************ (**) *****, ****** ****** (***) ***
****** ****** **** *** *** ****** **** ******* *********** **** ***, **** **. **-***, ****-**, ***, **********, *********, ********* ******, ***** (***) ***
****** ********* ******** ******* ****** ******* *********** **** **. **-**, ****** **, ******** ****, *********, ****** ******* ******, ***** (***) ***
****** ***** ***** ******** *.*.*. *********** ****** ****** ********** **, ******, *****, ******* (***) ***
****** ***** ******* ****** *.*.*. *********** ********* ***** **, ******** *********, *****, ******* (***) ***
****** ******** ****** ******** ****** **** ***. */*/* **** *************** **** ***. *********** *** ******* **, **** *********, *** ****** (**) *****, ****** ****** (***) ***
****** ******** ****** ****** *************** ******* *********** *** ****** **. ***, (*** ****** **. ***/*-*), *******-****, ******-*******,, *************, ******* ******, ***** (***) ***
****** ******** ****** **********, *** *********** *** **** ******, *********, *** ****** (**) *****, ****** ****** (***) ***
****** **** ****** *** ******* *************** ** *** *********** * ******** ****, *********, *** ****** (**) *****, ****** ****** (***) ***
****** ********* ****** *** *** ********** ******* *********** ****-*, **. **. ***/*, ***/*, ***/*, **** **. *-*/*, ***** ***, ***** ********** ****, ********* (*******), ********* (******), ************ (********), ************, ********* ******, ***** (***) ***
****** ******* ****** ******* *************** ******* ******* *********** ****** **. ***/* & ***/**, ******* *******, ********** ******, **********, ********* ******, ***** (***) ***
****** ***** ***** ******** *.*.*. *********** ****** ****** ********** **, ******, *****, ******* (***) ***
****** **** ****** *** **** ******, *** *********** ***** ***** ******* ******, *********, *** **** (**) *****, ****** ****** (***) ***
****** ***** ***** ******** *.*.*. *********** ****** ****** ********** **, ******, *****, ******* (***) ***
****** ********* ****** *** ********* ****** ******* *********** ****-***, ** **. ***/*, ***/*, ***/*, ***/* & ***/*, **** ** **** ***, *****, ***** ********** ****, *********, ********* ******, ************, ********* ******, ***** (***) ***

Download GenUS Drug Report


Download GenUS Detailed Report


To get detailed report Contact Us

GenUs Advanced Search




Expired
to
Expired
to


Brand Name Generic Name Strength Dosage Route of Administration Innovator ParaIV

Please contact contact@researchdelta.com to get more details.